- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Metastatic Castration Sensitive Prostate Cancer (mCSPC) in Australia
Total 99 results
-
Peter MacCallum Cancer Centre, AustraliaRecruitingProstate Cancer | Metastatic Castration-resistant Prostate Cancer | mCRPCAustralia
-
Peter MacCallum Cancer Centre, AustraliaRecruitingMetastatic Castration-resistant Prostate Cancer | mCRPCAustralia
-
BeiGeneTerminatedMetastatic Castration-Resistant Prostate Cancer (mCRPC) | Homologous Recombination Deficiency (HRD)United States, Australia, Puerto Rico, Spain
-
Peter MacCallum Cancer Centre, AustraliaRecruitingMetastatic Castration Resistant Prostate Cancer (mCRPC)Australia
-
Peter MacCallum Cancer Centre, AustraliaSuspendedPidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer (REPAIR)Metastatic Castration Resistant Prostate Cancer (mCRPC)Australia
-
Janux TherapeuticsRecruitingProstate Cancer | Metastatic Castration-resistant Prostate Cancer | Castration Resistant Prostatic CancerUnited States, Australia
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingMetastatic Castration-Resistant Prostate Cancer (mCRPC)Korea, Republic of, United States, Spain, France, Belgium, China, Taiwan, United Kingdom, Australia, Czechia, Hungary, Poland, Russian Federation
-
AstraZenecaRecruitingMetastatic Castration-Sensitive Prostate CancerUnited States, Canada, Spain, United Kingdom, Italy, Australia, Korea, Republic of, Belgium, Germany, Japan, Peru, France, China, India, Taiwan, Thailand, Austria, Brazil, Turkey, Malaysia, Finland, Netherlands, Chile, Hungary, Poland, Sw...
-
Janssen Research & Development, LLCActive, not recruitingMetastatic Castration-sensitive Prostate CancerUnited States, Italy, China, Korea, Republic of, Canada, Australia, United Kingdom, Hungary, France, Taiwan, Thailand, Germany, Malaysia, Denmark, Russian Federation, New Zealand, Ukraine, Bulgaria, Israel, Spain, Turkey, Sweden, Cz... and more
-
Merck Sharp & Dohme LLCOrion Corporation, Orion PharmaRecruitingProstatic Neoplasms | Metastatic Castration-resistant Prostate Cancer (mCRPC)Germany, United States, Puerto Rico, Israel, Australia, Korea, Republic of, Taiwan, China, Costa Rica, Guatemala, Spain, France, Hong Kong, Portugal, Romania
-
Janssen Research & Development, LLCApproved for marketingMetastatic Castration-resistant Prostate CancerBrazil, Austria, Estonia, Israel, Mexico
-
Peter MacCallum Cancer Centre, AustraliaRecruitingProstate Cancer | Metastatic Castration-resistant Prostate CancerAustralia
-
Peter MacCallum Cancer Centre, AustraliaActive, not recruitingProstate Cancer | Metastatic Castration-resistant Prostate CancerAustralia
-
Astellas Pharma Global Development, Inc.CompletedProstate Cancer | Castration-resistant Prostate Cancer | Metastatic Prostate CancerSpain, Taiwan, France, Algeria, Argentina, Australia, Austria, Brazil, Canada, Colombia, Egypt, Germany, Indonesia, Israel, Italy, Korea, Republic of, Lebanon, Mexico, Netherlands, New Zealand, Oman, Peru, Philippines, Saudi Arabia, Sin... and more
-
Australian and New Zealand Urogenital and Prostate...Astellas Pharma Inc; Endocyte; Prostate Cancer Research Alliance; National Health...Active, not recruitingMetastatic Castration-Resistant Prostate CancerAustralia
-
Peter MacCallum Cancer Centre, AustraliaCompletedMetastatic Castration Resistant Prostate CancerAustralia
-
Janssen Research & Development, LLCCompletedMetastatic Breast Cancer | Metastatic Castration-resistant Prostate CancerUnited States, Belgium, Spain, Germany, Sweden, Australia, United Kingdom
-
Astellas Pharma Global Development, Inc.Medivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedMetastatic Castration-resistant Prostate Cancer (mCRPC)France, Germany, Spain, United States, Argentina, Australia, Belgium, Canada, Chile, Czechia, Finland, Hungary, Israel, Italy, Korea, Republic of, New Zealand, Singapore, Sweden, Taiwan, United Kingdom
-
Hinova Pharmaceuticals Aus Pty LtdCompletedMetastatic Castration-resistant Prostate CancerAustralia
-
Hinova Pharmaceuticals USA, Inc.Active, not recruitingCastration-resistant Prostate Cancer | Prostate Cancer MetastaticGermany, Spain, Denmark, France, United Kingdom, Russian Federation, Poland, Australia, Italy, Netherlands, United States, Finland, Canada, Austria
-
Janssen-Cilag Ltd.RecruitingMetastatic Hormone-sensitive Prostate CancerFrance, Germany, Spain, Greece, Austria, United Kingdom
-
British Columbia Cancer AgencySanofi; Ozmosis Research Inc.UnknownMetastatic Castration-Resistant Prostatic CancerCanada, Australia
-
Janssen Research & Development, LLCRecruitingMetastatic Castrate-sensitive Prostate CancerUnited States, France, Mexico, Germany, Australia, Brazil, Canada, China, Poland
-
St Vincent's Hospital, SydneyRecruitingCastration-resistant Prostate Cancer | Homologous Recombination DeficiencyAustralia
-
BayerOrion Corporation, Orion PharmaCompletedProstate Cancer Non-Metastatic | Castration-ResistantBelgium, France, Poland, Spain, Canada, United States, Estonia, Portugal, Taiwan, Japan, Russian Federation, Finland, Germany, Austria, Czechia, Hungary, Australia, Brazil, South Africa, Latvia, Italy, United Kingdom, Turkey, Serbia, Ro... and more
-
Astellas Pharma Global Development, Inc.Medivation LLC, a wholly owned subsidiary of Pfizer Inc.Active, not recruitingMetastatic Hormone Sensitive Prostate CancerKorea, Republic of, Japan, United States, Argentina, Australia, Belgium, Canada, Chile, Denmark, Finland, France, Germany, Israel, Italy, Netherlands, New Zealand, Poland, Romania, Russian Federation, Slovakia, Spain, Sweden, Taiwan, United...
-
BayerOrion Corporation, Orion PharmaCompletedMetastatic Hormone-sensitive Prostate CancerBelgium, France, Sweden, China, Canada, United States, Spain, Taiwan, Japan, Finland, Korea, Republic of, Australia, Brazil, Czechia, Israel, Italy, Netherlands, Russian Federation, Bulgaria, United Kingdom, Germany, Poland, Mexico
-
SOTIO a.s.CompletedMetastatic Castration-resistant Prostate CancerUnited States, Spain, United Kingdom, Germany, Serbia, Portugal, Lithuania, Slovakia, Hungary, Netherlands, Croatia, France, Czechia, Poland, Austria, Belarus, Belgium, Bulgaria, Denmark, Italy, Latvia, Sweden
-
Astellas Pharma Europe Ltd.Medivation, Inc.CompletedMetastatic Castration Resistant Prostate CancerCzechia, Netherlands, Denmark, Italy, Austria, Belgium, Bulgaria, France, Germany, Greece, Hungary, Ireland, Portugal, Slovenia, Spain, United Kingdom
-
AmgenTerminatedMetastatic Castration-resistant Prostate CancerUnited States, Sweden, Spain, United Kingdom, Australia, Denmark
-
AmgenCompletedProstate Cancer | Metastatic Castration-resistant Prostate CancerUnited States, Belgium, Austria, Singapore, Australia, Netherlands, France, Japan, Taiwan, Canada
-
Merck Sharp & Dohme LLCActive, not recruitingMetastatic Hormone-Sensitive Prostate CancerTaiwan, Poland, United States, Australia, Austria, Brazil, Canada, Chile, China, Colombia, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Peru, Russian Federation, Spai... and more
-
German Cancer Research CenterUniversity Hospital Freiburg; ABX CRO; Friedrich-Alexander-Universität Erlangen-NürnbergCompletedProstate Cancer | Prostate Cancer Metastatic | High-risk Prostate Cancer | Lymphnode MetastasisAustria, Germany
-
Merck Sharp & Dohme LLCRecruitingMetastatic Castration-Resistant Prostate CancerUnited States, Austria, Canada, France, Germany, Ireland, Italy, Mexico, Netherlands, New Zealand, Poland, Russian Federation, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, Spain, Finland, Australia, Denmark
-
BayerActive, not recruitingBone Metastatic Castration-resistant Prostate CancerUnited Kingdom, France, Lithuania, Israel, Italy, Austria
-
BayerRecruitingMetastatic Castrate Resistant Prostate Cancer (mCRPC)Hong Kong, Spain, Taiwan, Australia, Turkey, France, Germany, Hungary, United Kingdom, Singapore, Korea, Republic of, Czechia, Italy, Finland, Israel, Austria, Lithuania, Poland, Russian Federation
-
St Vincent's Hospital, SydneyRecruitingMetastatic Prostate CancerAustralia
-
Australian and New Zealand Urogenital and Prostate...Peter MacCallum Cancer Centre, AustraliaRecruitingCastration Resistant Prostatic CancerAustralia
-
Telix Pharmaceuticals (Innovations) Pty LimitedCompletedMetastatic Prostate CancerAustralia
-
AstraZenecaMerck Sharp & Dohme LLC; Myriad Genetics, Inc.; Foundation Medicine, Inc.CompletedMetastatic Castration-resistant Prostate CancerUnited States, Canada, Denmark, Germany, Italy, Netherlands, Norway, Spain, Argentina, Taiwan, France, Korea, Republic of, Brazil, Japan, Turkey, United Kingdom, Austria, Australia, Israel, Sweden
-
BayerActive, not recruitingMetastatic Castration-resistant Prostate CancerUnited States, Austria, Czechia, Israel, Italy, Germany, United Kingdom, France, Mexico, Belgium, Canada, Colombia, Greece, Luxembourg, Netherlands, Spain, Denmark, Sweden, Argentina, Portugal
-
Royal North Shore HospitalTerminatedMetastatic Castrate- Resistant Prostate CancerAustralia
-
Telix International Pty LtdCompletedMetastatic Prostate CancerAustralia
-
AstraZenecaMerck Sharp & Dohme LLCActive, not recruitingMetastatic Castration-resistant Prostate CancerUnited States, Italy, Spain, Belgium, Canada, France, Korea, Republic of, United Kingdom, Brazil, Czechia, Turkey, Australia, Chile, Germany, Japan, Netherlands, Slovakia
-
Janssen Research & Development, LLCRecruitingMetastatic Castration-resistant Prostate NeoplasmsUnited States, Australia
-
MacroGenicsRecruitingProstate Cancer Recurrent | Immunotherapy | Androgen-Independent Prostatic Cancer | Androgen-Resistant Prostatic Cancer | Hormone Refractory Prostatic Cancer | Immune Checkpoint Inhibitor | Androgen-Independent Prostatic Neoplasms | Androgen-Insensitive Prostatic Cance | Inhibitory Checkpoint MoleculeUnited States, Spain, France, Belgium, United Kingdom, Poland, Georgia, Bulgaria, Puerto Rico, Australia
-
Movember FoundationKing's College London; Centre hospitalier de l'Université de Montréal (CHUM); University of California, San Francisco and other collaboratorsActive, not recruitingINTense ExeRcise for surviVAL Among Men With Metastatic Prostate Cancer (INTERVAL - GAP4) (INTERVAL)Metastatic Prostate CancerUnited States, Australia, Netherlands, Canada, United Kingdom, Germany, Ireland
-
Astellas Pharma Europe Ltd.Medivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedMetastatic Castration Resistant Prostate CancerBelgium, France, Spain, Austria, Czechia, Germany, Greece, Italy, Netherlands, Norway, Poland, Russian Federation, Sweden, Switzerland, Turkey, United Kingdom
-
PfizerAstellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedCastration-Resistant Prostate CancerUnited States, Canada, France, Spain, United Kingdom, Australia, Poland, Germany, Austria, Belgium, Netherlands, Italy, Chile, South Africa, Argentina
-
Medical University of ViennaRecruitingLocally Advanced and Metastatic Prostate CancerAustria